Navigation Links
Second Successful Quigley QR-443 Study Suggests Method of Action,Relevant to Broad Range of Chronic Inflammatory Diseases - Human,Study to Follow -

processes and pathways - a disruption of homeostasis.

Dr. Richard Rosenbloom EVP/COO Quigley Pharma, Inc. stated, "We are encouraged by these and previous results and are looking forward to subjecting the compound to more rigorous tests to support eventual commercialization."

About The Study

The study results demonstrated a correlation to the levels of serum IL-6 and the degree of cachexia. Mice responding to QR-443 treatment had much lower levels of serum IL-6 which correlated with reduced cachexia, compared to non responders and the control population who had elevated IL-6 and dramatic weight loss. These findings are in agreement with several previous studies demonstrating the increased presence of IL-6 in the etiology of cachexia and other diseases related to inflammation.

The purpose of the study was to replicate positive oral dose response trials in BALB/C mice as well as to investigate the possible relationship of the levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) cytokines which have been associated with the severity and progression of cachexia. In this experiment a larger group of mice was used, their weight being recorded and blood being drawn prior to the onset of cachexia and then at the peak of cachexia which marked the end of the experiment. There was no correlation between the levels of TNF-alpha and the severity of cachexia and levels of IFN-gamma were lower than the detectable assay level.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will allow the aforementioned Compound to be tested in humans or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its Cold Reme
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:10/9/2008)...paign to Spread Awareness and Bring Hope to Millio...swire-USNewswire/ -- 133 million children,across t...uch as natural,disaster, civil war, and disease. S...World Orphan Week by calling attention to the need...ews Release, go to:, http://www.prnewswire.com/m...
(Date:10/9/2008)...nal Science Institute, Navigenics, Affymetrix and,...N DIEGO, Oct. 9 /- A consortium of he...ined forces in a first-of-its-kind,research study ...c testing,on people who choose to receive such scr...oping certain diseases., Sponsored by Scripps Tra...
(Date:10/8/2008)...eday Inform Treatments for Spinal Cord, Other Nerv...Newswire/ -- A protein that enables,nerve cells to...ontrolling,the developing nervous system. Research...o form among nerve cells may provide a basis for e...s to their nervous system,including spinal cord i...
(Date:10/8/2008)...am to evaluate TAXUS(R) Element(TM) Platinum Chrom..., Mass., Oct. 8 /- Boston S...d that it has completed enrollment in,the PERSEUS ...neration,TAXUS(R) Element(TM) paclitaxel-eluting c...rolled nearly 1,500 patients at 100 U.S. and,inter...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Your belly fat could be making you hungrier 17023 1Your belly fat could be making you hungrier 17023 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 1GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 3The Miracle of Funding by State and Local Pension Plans 17016 1The Miracle of Funding by State and Local Pension Plans 17016 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 1AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 3
...WIRE)--Jun 1, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, ...mpany developing novel therapeutics to treat cance...n of two abstracts in the,2007 Annual Meeting prog...ng of the American Society of Clinical Oncology (A...or the first time full data from a,randomized Phas...
... 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ...se 2,monotherapy trial showing that tanespimycin d... patients with metastatic melanoma,including one ...d,prior chemotherapy (within 6 weeks of initiation...on-free survival for more than,six months and 20% ...
Other Medicine Technology:OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...test mysteries that has been plaguing mankind is t... have finally been able to unravel the mystery wit...y scientists after a study of more than 1000 peopl...eed to be answered on a scale of 1 to 10 and the s...
...by researchers in the Institute of Preventive Medi...asionally may be beneficial in countering dementia...that people who drank wine weekly or monthly were ...ia, said that the findings are important because t...
...earchers of the Harvard Medical School, of more th...amine antagonists, i.e. anti-psychotics, for eithe... have an increased risk of breast cancer. The stud... taking dopamine antagonists and 55,000 women who ...
...ished in an online issue of Nature Medicine by res... a stunning discovery of a bold new type of vaccin...gs. The study which was carried// out on monkeys s...med and adapted in humans may signal a major new t...
Other Medicine News:Health News:The Happiness Formula.... 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: